Key clinical point: Upadacitinib showed sustained efficacy through 52 weeks in adults and adolescents with moderate-to-severe atopic dermatitis (AD) along with an acceptable safety profile.
Major finding: At week 52, a 75% improvement in Eczema Area and Severity Index (EASI75) was achieved by 82.0% and 79.1% of patients continuing 15 mg upadacitinib and 84.9% and 84.3% of patients continuing 30 mg upadacitinib in Measure Up 1 and Measure Up 2, respectively. More than 80% of patients who switched from placebo to upadacitinib at week 16 achieved EASI75 at week 52. No new adverse events were reported.
Study details: Findings are from a 52-week analysis of two ongoing phase 3 trials, Measure Up 1 and Measure Up 2, including 1,609 adults and adolescents with moderate-to-severe AD who were randomly assigned to receive 15 mg upadacitinib once daily, 30 mg upadacitinib, or placebo .
Disclosures: This study was funded by AbbVie. Three authors reported ties with various sources, including AbbVie, with some receiving payments or personal fees and being employees or stockholders of AbbVie.
Source: Simpson EL et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: Analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatol. 2022 (Mar 9). Doi: 10.1001/jamadermatol.2022.0029